News
Venetoclax-HMA combo promising for AML in patients 65+
MADRID – For older patients with AML, there are few good therapeutic options ... until now.
News
All FDA panel members go thumbs up for CTL019 in relapsed/refractory childhood ALL
Steps need to be taken to mitigate the risk of cytokine release syndrome and neurologic events and the potential for secondary malignancies.
News
Enasidenib monotherapy responses in 37% with relapsed/refractory AML and IDH2 mutations
MADRID – Durable complete responses were associated with overall survival of greater than 8 months.
News
Copanlisib makes inroads against relapsed/refractory follicular lymphoma
LUGANO, SWITZERLAND – New PI3K inhibitor promises better safety and efficacy for ongoing treatment.
News
Tazemetostat active against follicular lymphoma with EZH2 mutation
LUGANO, SWITZERLAND - Patients most likely to respond to tazemetostat were those with activating mutations in EZH2 and MYD88.
News
Ibrutinib/buparlisib looks good for relapsed mantle cell lymphoma
LUGANO, SWITZERLAND – The overall response rate among patients with mantle cell lymphoma in a phase I/IB dose escalation study was 100%,...
News
T receptor diversity may predict BCP-ALL response to blinatumomab
MADRID – Not seeing the responses you want in BCP-ALL? There may be a predictable reason.
News
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed...
News
CARs race for supremacy against aggressive non-Hodgkin lymphoma
MADRID - Two chimeric antigen receptor T cell (CAR-T) constructs are showing promising activity against treatment-refractory, aggressive forms of...
News
Gene editing aims to recreate beneficial mutation in SCD, beta-thalassemia
Production of fetal hemoglobin is protective against symptoms of these diseases.
News
Ibrutinib dons new anti-GVHD hat
MADRID – Talk about versatility: Ibrutinib (Imbruvica), a drug with marked activity against B-cell malignancies, also appears to be a safe and...
News
Overall survival better in advanced Hodgkin lymphoma with shorter eBEACOPP
Good news for patients taking this very toxic chemotherapy regimen.
News
Major bleeding deaths may outweigh VTE risk in older cancer patients
Anticoagulation should be considered, carefully, on a patient-by-patient basis.
News
Infections may trigger leukemia in the genetically susceptible
MADRID – Leukemia may have a previously unconsidered cause in some patients.
News
Twofer drug blocks SYK/JAK pathways in advanced NHL
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK)...